NEW YORK, June 17, 2021 /PRNewswire/ —
The non-insulin diabetes therapeutics market is poised to grow by USD 22.95 billion during 2021-2025, progressing at a CAGR of over 10% during the forecast period.
Technavio’s in-depth market research reports include value chain analysis and validation techniques to help industry leaders improve their business.
Download FREE Sample Report
The report on the non-insulin diabetes therapeutics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by factors such as the increasing number of people with type 2 diabetes, the growing prevalence of diabetes among people aged 6-19 and 35-50, and the recent product approvals.
The non-insulin diabetes therapeutics market analysis includes type and geography landscape segments. This study identifies the recent product approvals as one of the prime reasons driving the non-insulin diabetes therapeutics market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The non-insulin diabetes therapeutics market covers the following areas:
Non-insulin Diabetes Therapeutics Market Sizing
Non-insulin Diabetes Therapeutics Market Forecast
Non-insulin Diabetes Therapeutics Market Analysis
Companies Mentioned
- Abbott Laboratories
- AstraZeneca Plc
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Sanofi SA
Related Reports on Health Care Include:
Global Type 1 Diabetes Drugs Market– The type 1 diabetes drugs market is segmented by product (long-acting insulins, rapid-acting insulins, premixed insulins, and non-insulin drugs) and geography (North America, Europe, Asia, and ROW).
Download FREE Sample Report
Global Type 2 Diabetes Market– The type 2 diabetes market is segmented by drug class (insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, and others) and geography (North America, Europe, Asia, and ROW).
Download FREE Sample Report
Key Topics Covered:
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020- 2025
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- DPP4 inhibitor – Market size and forecast 2020-2025
- GLP-1 receptor agonist – Market size and forecast 2020-2025
- SGLT2 inhibitor – Market size and forecast 2020-2025
- Others – Market size and forecast 2020-2025
- Market opportunity by Type
Customer landscape
- Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2020-2025
- Europe – Market size and forecast 2020-2025
- Asia – Market size and forecast 2020-2025
- ROW – Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Abbott Laboratories
- AstraZeneca Plc
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Sanofi SA
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Newsroom: https://www.technavio.com/news/non-insulin-diabetes-therapeuticsmarket
Report Page: https://www.technavio.com/report/non-insulin-diabetes-therapeutics-market-industry-analysis
View original content to download multimedia:http://www.prnewswire.com/news-releases/non-insulin-diabetes-therapeutics-market-22-95-billion-growth-expected-during-2021-202517000-technavio-research-reports-301315173.html
SOURCE Technavio
